REG - ReNeuron Group plc - New Scientific Advisory Board

ReNeuronAnnouncement

03/04/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230403:nRSC0070Va&default-theme=true

RNS Number : 0070V  ReNeuron Group plc  03 April 2023

ReNeuron Group plc

("ReNeuron" or the "Company")

 

New Scientific Advisory Board

 

ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome
technologies, announces the appointment of Prof. Giuseppe (Beppe) Battaglia,
Prof. Edit I Buzás, Prof. Dr. rer. Nat. Bernd Giebel and Prof. Kenneth W.
Witwer to a newly established Scientific Advisory Board (SAB), chaired by
Prof. Stefano Pluchino.

 

This new SAB, composed of leading academics and industry executives, brings a
world-class breadth of expertise across the extracellular vesicle (EV) field.
Its role is to advise the Company on scientific matters relating to its
exosome platform research and development strategy.

 

For additional information on ReNeuron's Scientific Advisory Board and its
members, please visit the Company's website via the following link:
https://www.reneuron.com/about-us/advisory-board/
(https://www.reneuron.com/about-us/advisory-board/) .

 

Stefano Pluchino, Chair of the SAB, commented: "I am delighted that we have
attracted such renowned EV experts to join the ReNeuron SAB and it is a
privilege to be the Chair of the board. I very much look forward to working
alongside them and the Company as we seek to progress the development of the
Company's stem cell-derived exosome-based drug delivery platform.

 

"On behalf of the Company, I would also like to take the opportunity to thank
the former members of the old Scientific Advisory Board for all the advice and
support provided during their membership."

 

 
ENDS

Enquiries:

 

 ReNeuron                                                     www.reneuron.com/investors (http://www.reneuron.com/investors)
 Iain Ross, Executive Chairman                                Via Walbrook PR
 John Hawkins, Chief Financial Officer

 Allenby Capital Limited (Nominated Adviser and Broker)       +44 (0)20 3328 5656
 James Reeve/George Payne (Corporate Finance)
 Stefano Aquilino (Sales & Corporate Broking)

 Walbrook PR (Media & Investor Relations)                     +44 (0)20 7933 8780 or reneuron@walbrookpr.com
                                                              (mailto:reneuron@walbrookpr.com)
 Paul McManus / Alice Woodings  +44 (0)7980 541 893 / +44 (0)7407 804 654

 

About ReNeuron

ReNeuron has developed a proprietary stem cell-derived, exosome-based, drug
delivery platform with customisable cellular targeting capabilities for the
delivery of complex drug modalities.

 

Through the generation of several unique and scalable exosome producer cell
lines, our CustomEX™ platform can be optimised for specific tissues targets
and payloads leading to improvements in therapeutic outcome and a reduction in
off-target effects. ReNeuron offers a delivery mechanism for a variety of
payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its
conditionally immortalised induced pluripotent stem cell (iPSC) platform, the
Company can make allogeneic tissue cells of choice and has the potential to
produce exosomes with tissue specific targeting ability.

 

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.
For further information visit www.reneuron.com (http://www.reneuron.com/)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDZGFFDMZGFZM